Second quarter 2026 saw 40% YoY net sales growth to $1.49B, driven by strong Opzelura and core business performance, including a $246M one-time benefit. Full-year guidance was raised, with robust pipeline progress and multiple regulatory milestones expected in 2H26.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.